{"id":308,"date":"2020-06-16T00:28:50","date_gmt":"2020-06-16T00:28:50","guid":{"rendered":"https:\/\/mikemcmahon.info\/coach\/?p=308"},"modified":"2020-06-16T00:35:32","modified_gmt":"2020-06-16T00:35:32","slug":"quidel","status":"publish","type":"post","link":"https:\/\/mikemcmahon.info\/coach\/quidel\/","title":{"rendered":"Quidel"},"content":{"rendered":"\n

One sentence overview<\/strong>:\u00a0Quidel Corporation is a manufacturer of diagnostic healthcare products that are sold worldwide.<\/p>\n\n\n\n

Quidel Ticker\u00a0\u00a0QDEL\u00a0\u00a0<\/p>\n\n\n\n

6\/15\/2020 Stock Price $203.44<\/p>\n\n\n\n

6\/15\/2020 Market Cap $8.5B<\/p>\n\n\n\n

Total Shares Outstanding Recent Quarterly Report\u00a0 43 million shares<\/p>\n\n\n\n

<\/td>Jan 2020<\/td>March Low<\/td>Apr 30<\/td>6\/15\/2020<\/td>YTD %<\/td><\/tr>
Quidel<\/td>$75<\/td>$74<\/td>$139<\/td>$203<\/td>169%<\/td><\/tr>
S&P 500<\/td>3231<\/td>2237<\/td>2585<\/td>3067<\/td>-5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Quidel Investor Relations Page<\/p>\n\n\n\n

https:\/\/ir.quidel.com\/home\/default.aspx<\/a><\/p>\n\n\n\n

Quidel SEC Page<\/p>\n\n\n\n

https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?CIK=qdel&owner=exclude&action=getcompany<\/a><\/p>\n\n\n\n

Quidel Glassdoor Ratings<\/p>\n\n\n\n

https:\/\/www.glassdoor.com\/Reviews\/Quidel-Reviews-E1469.htm<\/a><\/p>\n\n\n\n

Quidel Overview<\/strong><\/p>\n\n\n\n

Quidel commenced operations in 1979 and launched its first products in 1984. Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged. Quidel\u2019s core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development.<\/p>\n\n\n\n

Products<\/strong><\/p>\n\n\n\n

Quidel\u2019s current products fall generally into these categories: (1) lateral flow, where it focuses on infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products.<\/p>\n\n\n\n

On May 8, 2020 the U.S. Food and Drug Administration (FDA) has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. These tests are administered in the doctor\u2019s office.<\/p>\n\n\n\n

Business and Financial Drivers<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Competition<\/strong><\/p>\n\n\n\n

Quidel\u2019s\u00a0top\u00a0competitors\u00a0include GlySure, Surgical Care Affiliates, CareView Communications and Halfpenny Technologies.\u00a0<\/p>\n\n\n\n

Future Outlook<\/strong><\/p>\n\n\n\n

The recent pandemic will provide Quidel with a significant increase in revenue and presence in doctor\u2019s offices. As a result, Quidel\u2019s other testing products will see an increase in usage after the pandemic ends.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Disclaimer: I do not have any formal recommendation for or against this stock, so don\u2019t buy or sell stocks based solely on what you read.<\/em><\/p>\n\n\n\n

Interested in receiving a weekly recap of reviewed stocks? Sign up.<\/p>\n\n\n\n